-
Je něco špatně v tomto záznamu ?
Analytical quality by design in the development of a solvent-modified micellar electrokinetic chromatography method for the determination of sitagliptin and its related compounds
B. Pasquini, R. Gotti, M. Villar-Navarro, M. Douša, L. Renai, M. Del Bubba, S. Orlandini, S. Furlanetto
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články
- MeSH
- chromatografie micelární elektrokinetická kapilární * MeSH
- dodecylsíran sodný MeSH
- micely * MeSH
- reprodukovatelnost výsledků MeSH
- rozpouštědla MeSH
- sitagliptin fosfát MeSH
- Publikační typ
- časopisecké články MeSH
A solvent-modified micellar electrokinetic chromatography method was developed following the Quality by Design approach for the simultaneous determination of sitagliptin (SIT), an oral antihyperglycemic drug, and its main impurities derived from the synthesis process. The separation system was identified in the scouting phase and was made by sodium dodecyl sulphate (SDS) micelles with the addition of n-butanol and methanol. The knowledge space was investigated through an asymmetric screening matrix, taking into consideration eight critical method parameters (CMPs) involving the composition of the background electrolyte in terms of buffer concentration and pH, the concentration of surfactants and organic modifiers, and voltage. The critical method attributes (CMAs) were identified as analysis time and the distance between the tail of the electroosmotic flow system peak and the front edge of impurity I1 (sitagliptin triazole hydrochloride). A Box-Behnken Design was used in response surface methodology for calculating the quadratic models relating the CMPs to the CMAs. From the models it was possible to compute the method operable design region (MODR) through Monte-Carlo simulations. The MODR was identified in the probability maps as the multidimensional zone where the risk of failure to achieve the desired values for the CMAs was lower than 10 %. The experimental conditions corresponding to the working point, with the MODR interval, were the following: background electrolyte, 14 (10-18) mM borate buffer pH 9.20, 100 mM SDS, 13.6 (11.1-16.0) %v/v n-butanol, 6.7 (4.5-8.8) %v/v methanol; voltage and temperature were set to 28 kV and 22 °C, respectively. The developed CE method was validated in accordance with International Council for Harmonisation guidelines and was applied to the analysis of SIT tablets. The routine analysis for the quality control of the pharmaceutical product could be conducted in about 11 min.
Department of Pharmacy and Biotechnology University of Bologna Via Belmeloro 6 40126 Bologna Italy
Zentiva k s Praha a Sanofi Company U Kabelovny 130 102 37 Praha 10 Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21018371
- 003
- CZ-PrNML
- 005
- 20210830095945.0
- 007
- ta
- 008
- 210728s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jpba.2021.114163 $2 doi
- 035 __
- $a (PubMed)34052552
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Pasquini, Benedetta $u Department of Chemistry "U. Schiff", University of Florence, Via U. Schiff 6, Via della Lastruccia 3-13, 50019, Sesto Fiorentino, Florence, Italy. Electronic address: benedetta.pasquini@me.com
- 245 10
- $a Analytical quality by design in the development of a solvent-modified micellar electrokinetic chromatography method for the determination of sitagliptin and its related compounds / $c B. Pasquini, R. Gotti, M. Villar-Navarro, M. Douša, L. Renai, M. Del Bubba, S. Orlandini, S. Furlanetto
- 520 9_
- $a A solvent-modified micellar electrokinetic chromatography method was developed following the Quality by Design approach for the simultaneous determination of sitagliptin (SIT), an oral antihyperglycemic drug, and its main impurities derived from the synthesis process. The separation system was identified in the scouting phase and was made by sodium dodecyl sulphate (SDS) micelles with the addition of n-butanol and methanol. The knowledge space was investigated through an asymmetric screening matrix, taking into consideration eight critical method parameters (CMPs) involving the composition of the background electrolyte in terms of buffer concentration and pH, the concentration of surfactants and organic modifiers, and voltage. The critical method attributes (CMAs) were identified as analysis time and the distance between the tail of the electroosmotic flow system peak and the front edge of impurity I1 (sitagliptin triazole hydrochloride). A Box-Behnken Design was used in response surface methodology for calculating the quadratic models relating the CMPs to the CMAs. From the models it was possible to compute the method operable design region (MODR) through Monte-Carlo simulations. The MODR was identified in the probability maps as the multidimensional zone where the risk of failure to achieve the desired values for the CMAs was lower than 10 %. The experimental conditions corresponding to the working point, with the MODR interval, were the following: background electrolyte, 14 (10-18) mM borate buffer pH 9.20, 100 mM SDS, 13.6 (11.1-16.0) %v/v n-butanol, 6.7 (4.5-8.8) %v/v methanol; voltage and temperature were set to 28 kV and 22 °C, respectively. The developed CE method was validated in accordance with International Council for Harmonisation guidelines and was applied to the analysis of SIT tablets. The routine analysis for the quality control of the pharmaceutical product could be conducted in about 11 min.
- 650 12
- $a chromatografie micelární elektrokinetická kapilární $7 D020374
- 650 12
- $a micely $7 D008823
- 650 _2
- $a reprodukovatelnost výsledků $7 D015203
- 650 _2
- $a sitagliptin fosfát $7 D000068900
- 650 _2
- $a dodecylsíran sodný $7 D012967
- 650 _2
- $a rozpouštědla $7 D012997
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Gotti, Roberto $u Department of Pharmacy and Biotechnology, University of Bologna, Via Belmeloro 6, 40126, Bologna, Italy. Electronic address: roberto.gotti@unibo.it
- 700 1_
- $a Villar-Navarro, Mercedes $u Department of Analytical Chemistry, University of Seville, c/Prof. García González, s/n., 41012, Seville, Spain. Electronic address: mvn@us.es
- 700 1_
- $a Douša, Michal $u Zentiva, k.s. Praha, a Sanofi Company, U Kabelovny 130, 102 37, Praha 10, Czech Republic. Electronic address: michal.dousa@seznam.cz
- 700 1_
- $a Renai, Lapo $u Department of Chemistry "U. Schiff", University of Florence, Via U. Schiff 6, Via della Lastruccia 3-13, 50019, Sesto Fiorentino, Florence, Italy. Electronic address: lapo.renai@unifi.it
- 700 1_
- $a Del Bubba, Massimo $u Department of Chemistry "U. Schiff", University of Florence, Via U. Schiff 6, Via della Lastruccia 3-13, 50019, Sesto Fiorentino, Florence, Italy. Electronic address: massimo.delbubba@unifi.it
- 700 1_
- $a Orlandini, Serena $u Department of Chemistry "U. Schiff", University of Florence, Via U. Schiff 6, Via della Lastruccia 3-13, 50019, Sesto Fiorentino, Florence, Italy. Electronic address: serena.orlandini@unifi.it
- 700 1_
- $a Furlanetto, Sandra $u Department of Chemistry "U. Schiff", University of Florence, Via U. Schiff 6, Via della Lastruccia 3-13, 50019, Sesto Fiorentino, Florence, Italy. Electronic address: sandra.furlanetto@unifi.it
- 773 0_
- $w MED00002894 $t Journal of pharmaceutical and biomedical analysis $x 1873-264X $g Roč. 202, č. - (2021), s. 114163
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34052552 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830095945 $b ABA008
- 999 __
- $a ok $b bmc $g 1689486 $s 1138815
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 202 $c - $d 114163 $e 20210524 $i 1873-264X $m Journal of pharmaceutical and biomedical analysis $n J Pharm Biomed Anal $x MED00002894
- LZP __
- $a Pubmed-20210728